Form D · Biotechnology
GENOPLAN INC.
New York, NY · CIK 0001669736
Offering snapshot reported Mar 21, 2016 · SEC filing
- Reported sold
- $4.2M Offering amount: $5M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 14, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 21, 2016 | Initial | $4,200,007 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-259639
Source: Form D, filed Mar 21, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Byungkyu Kang | Director, Executive, Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
C/O Wework 54 W. 40 Th Street
New York, NY, 10018
New York, NY, 10018